Cargando…
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674560/ https://www.ncbi.nlm.nih.gov/pubmed/36805887 http://dx.doi.org/10.1053/j.seminhematol.2022.11.001 |
_version_ | 1784833182029316096 |
---|---|
author | Haggenburg, Sabine Hofsink, Quincy Rutten, Caroline E. Nijhof, Inger S. Hazenberg, Mette D. Goorhuis, Abraham |
author_facet | Haggenburg, Sabine Hofsink, Quincy Rutten, Caroline E. Nijhof, Inger S. Hazenberg, Mette D. Goorhuis, Abraham |
author_sort | Haggenburg, Sabine |
collection | PubMed |
description | Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies. |
format | Online Article Text |
id | pubmed-9674560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96745602022-11-21 SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies Haggenburg, Sabine Hofsink, Quincy Rutten, Caroline E. Nijhof, Inger S. Hazenberg, Mette D. Goorhuis, Abraham Semin Hematol Article Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies. The Author(s). Published by Elsevier Inc. 2022-10 2022-11-19 /pmc/articles/PMC9674560/ /pubmed/36805887 http://dx.doi.org/10.1053/j.seminhematol.2022.11.001 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Haggenburg, Sabine Hofsink, Quincy Rutten, Caroline E. Nijhof, Inger S. Hazenberg, Mette D. Goorhuis, Abraham SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies |
title | SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies |
title_full | SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies |
title_fullStr | SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies |
title_full_unstemmed | SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies |
title_short | SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies |
title_sort | sars-cov-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674560/ https://www.ncbi.nlm.nih.gov/pubmed/36805887 http://dx.doi.org/10.1053/j.seminhematol.2022.11.001 |
work_keys_str_mv | AT haggenburgsabine sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies AT hofsinkquincy sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies AT ruttencarolinee sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies AT nijhofingers sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies AT hazenbergmetted sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies AT goorhuisabraham sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies |